New drug cocktail aims to wipe out breast cancer before surgery
NCT ID NCT04877821
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 2 trial tested a combination of sintilimab (an immunotherapy), anlotinib (a drug that blocks blood vessel growth), and standard chemotherapy in 29 people with early-stage triple-negative breast cancer. The treatment was given before surgery to shrink or eliminate the tumor. The main goal was to see how many patients had no cancer left at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sintilimab (immunotherapy), anlotinib (anti-angiogenesis drug), nab-paclitaxel, and carboplatin (chemotherapy)
What this could lead to
If successful, this combination could become a new pre-surgery treatment option for early triple-negative breast cancer, potentially improving the chance of eliminating all cancer before surgery.
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply to all patients. The combination also carries risks of side effects from immunotherapy, anti-angiogenesis drugs, and chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NeoSACT
Guangzhou, Guangdong, 510080, China